APA

Papp K. A., Kaufmann R., Thaçi D., Hu C., Sutherland D. & Rohane P. (20140923). Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study. : Journal of the European Academy of Dermatology and Venereology : JEADV.

Chicago

Papp K A, Kaufmann R, Thaçi D, Hu C, Sutherland D and Rohane P. 20140923. Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study. : Journal of the European Academy of Dermatology and Venereology : JEADV.

Harvard

Papp K. A., Kaufmann R., Thaçi D., Hu C., Sutherland D. and Rohane P. (20140923). Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study. : Journal of the European Academy of Dermatology and Venereology : JEADV.

MLA

Papp K A, Kaufmann R, Thaçi D, Hu C, Sutherland D and Rohane P. Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study. : Journal of the European Academy of Dermatology and Venereology : JEADV. 20140923.